The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Tamoxifen Resistance in Breast Cancer
Open accessAbstract
Tamoxifen is a central component of the treatment of estrogen receptor (ER)-positive breast cancer as a partial agonist of ER. It has been clinically used for the last 30 years and is currently available as a chemopreventive agent in women with high risk for breast cancer. The most challenging issue with tamoxifen use is the development of resistance in an initially responsive breast tumor. This review summarizes the roles of ER as the therapeutic target of tamoxifen in cancer treatment, clinical values and issues of tamoxifen use, and molecular mechanisms of tamoxifen resistance. Emerging knowledge on the molecular mechanisms of tamoxifen resistance will provide insight into the design of regimens to overcome tamoxifen resistance and discovery of novel therapeutic agents with a decreased chance of developing resistance as well as establishing more efficient treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
Shiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729
ERβ: Identification and characterization of a novel human estrogen receptor
Mosselman, S., Polman, J., & Dijkema, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00782-x · Cited by 2,269
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Estrogen Carcinogenesis in Breast Cancer
Yager, J. D., & Davidson, N. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmra050776 · Cited by 1,862
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857 · cited 1×
“Molecular pathways for ER-mediated signaling transduction are found elsewhere (Heldring et al., 2007) and therefore, they will not be discussed in this review.”
BackgroundCuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674
AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer
Anzick, S. L., Kononen, J., Walker, R. L., Azorsa, D. O., Tanner, M. M., Guan, X.-Y., Sauter, G., Kallioniemi, O.-P., Trent, J. M., & Meltzer, P. S. (1997) · Science · doi:10.1126/science.277.5328.965 · Cited by 1,639
Björnström, L., & Sjöberg, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0486 · Cited by 1,362
Sequence and Expression of Human Estrogen Receptor Complementary DNA
Greene, G. L., Gilna, P., Waterfield, M., Baker, A., Hort, Y., & Shine, J. (1986) · Science · doi:10.1126/science.3753802 · Cited by 1,311
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji250 · Cited by 1,118
Estrogens, Progestogens, Normal Breast Cell Proliferation, and Breast Cancer Risk
Pike, M. C., Spicer, D. V., Dahmoush, L., & Press, M. F. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036102 · Cited by 1,010
Sheridan, C., Kishimoto, H., Fuchs, R. K., Mehrotra, S., Bhat-Nakshatri, P., Turner, C. H., Goulet, R., Badve, S., & Nakshatri, H. (2006) · Breast Cancer Research · doi:10.1186/bcr1610 · Cited by 993
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Role of oxidative stress and DNA damage in human carcinogenesis
Kryston, T. B., Georgiev, A. B., Pissis, P., & Georgakilas, A. G. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2010.12.016 · Cited by 930
(2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70385-6 · Cited by 919
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Howell, A. (1998) · PubMed · Cited by 901
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Henderson, B. E., & Feigelson, H. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.427 · Cited by 821
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
Benz, C. C., Scott, G. K., Sarup, J. C., Johnson, R. M., Tripathy, D., Coronado, E., Shepard, H. M., & Osborne, C. K. (1992) · Breast Cancer Research and Treatment · doi:10.1007/bf01961241 · Cited by 750
Tzukerman, M. T. (1994) · Molecular Endocrinology · doi:10.1210/me.8.1.21 · Cited by 671
Howell, A., Robertson, J. F. R., Quaresma Albano, J., Aschermannova, A., Mauriac, L., Kleeberg, U. R., Vergote, I., Erikstein, B., Webster, A., & Morris, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.057 · Cited by 671
Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660 · cited 1×
“The nuclear receptor corepressor 1, NcoR1, has been shown to associate with ER in the presence of a metabolite of tamoxifen, trans-hydroxytamoxifen, and knockdown of NcoR1 mediated agonistic action of this antiestrogen metabolite instead of antagonistic activity (Lavinsky et al., 1998).”
BackgroundDissociation between steroid receptor expression and cell proliferation in the human breast.
Clarke, R. B., Howell, A., Potten, C. S., & Anderson, E. J. (1997) · PubMed · Cited by 625
Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020299707510 · Cited by 585
The role of estrogen in the initiation of breast cancer
Russo, J., & Russo, I. H. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.004 · Cited by 575
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
Fundamental Aspects of Reactive Oxygen Species, or What's the Matter with Oxygen?
FRIDOVICH, I. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07814.x · Cited by 541
Croker, A. K., Goodale, D., Chu, J., Postenka, C., Hedley, B. D., Hess, D. A., & Allan, A. L. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00455.x · Cited by 525
Bursch, W., Ellinger, A., Kienzl, H., Török, L., Pandey, S., Sikorska, M., Walker, R., & Hermann, R. S. (1996) · Carcinogenesis · doi:10.1093/carcin/17.8.1595 · Cited by 516
DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies
Lyko, F., & Brown, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji311 · Cited by 510
A MONOHYDROXYLATED METABOLITE OF TAMOXIFEN WITH POTENT ANTIOESTROGENIC ACTIVITY
JORDAN, V. C., COLLINS, M. M., ROWSBY, L., & PRESTWICH, G. (1977) · Journal of Endocrinology · doi:10.1677/joe.0.0750305 · Cited by 506
Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810818 · Cited by 496
Estrogen receptor interaction with co-activators and co-repressors☆
Klinge, C. M. (2000) · Steroids · doi:10.1016/s0039-128x(99)00107-5 · Cited by 491
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation
Angel, P., & Karin, M. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(91)90011-9 · Cited by 450
(1988) · PubMed · Cited by 416
Use of tamoxifen for breast cancer: twenty-eight years later.
Jaiyesimi, I. A., Buzdar, A. U., Decker, D. A., & Hortobagyi, G. N. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.2.513 · Cited by 413
Cavalieri, E., Chakravarti, D., Guttenplan, J., Hart, E., Ingle, J., Jankowiak, R., Muti, P., Rogan, E., Russo, J., Santen, R., et al. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.03.001 · Cited by 409
Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., Láng, I., Wardley, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70270-4 · Cited by 406
Current status of estrogen and progesterone receptors in breast cancer
McGuire, W. L., Horwitz, K. B., Pearson, O. H., & Segaloff, A. (1977) · Cancer · doi:10.1002/1097-0142(197706)39:6<2934::aid-cncr2820390680>3.0.co;2-p · Cited by 388
Estrogen Receptor Activation Function 1 Works by Binding p160 Coactivator Proteins
Webb, P. (1998) · Molecular Endocrinology · doi:10.1210/me.12.10.1605 · Cited by 384
Russo, J., Ao, X., Grill, C., & Russo, I. H. (1999) · Breast Cancer Research and Treatment · doi:10.1023/a:1006186719322 · Cited by 361
Paridaens, R. J., Dirix, L. Y., Beex, L. V., Nooij, M., Cameron, D. A., Cufer, T., Piccart, M. J., Bogaerts, J., & Therasse, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4659 · Cited by 319
Selective estrogen receptor modulation
Jordan, V. C. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00059-5 · Cited by 315
Wegman, P., Elingarami, S., Carstensen, J., Stål, O., Nordenskjöld, B., & Wingren, S. (2007) · Breast Cancer Research · doi:10.1186/bcr1640 · Cited by 288
Breast cancer, stem/progenitor cells and the estrogen receptor
Dontu, G., El-Ashry, D., & Wicha, M. S. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.05.011 · Cited by 288
Mürdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P. A., Fehm, T., Eichelbaum, M., Schwab, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.27 · Cited by 270
Triple negative breast cancers: Clinical and prognostic implications
Dawson, S. J., Provenzano, E., & Caldas, C. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70013-9 · Cited by 266
Peroxiredoxins in breast carcinoma.
Karihtala, P., Mäntyniemi, A., Kang, S. W., Kinnula, V. L., & Soini, Y. (2003) · PubMed · Cited by 261
Potential Mechanisms of Estrogen Quinone Carcinogenesis
Bolton, J. L., & Thatcher, G. R. J. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700191p · Cited by 241
Crewe, H. K., Notley, L. M., Wunsch, R. M., Lennard, M. S., & Gillam, E. M. J. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.869 · Cited by 241
Chapter 1: Developmental, Cellular, and Molecular Basis of Human Breast Cancer
Russo, J., Hu, Y.-F., Yang, X., & Russo, I. H. (2000) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a024241 · Cited by 241
New Strategies in Estrogen Receptor–Positive Breast Cancer
Johnston, S. R. D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1823 · Cited by 230
Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo
Schiff, R. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211
Qadir, M. A., Kwok, B., Dragowska, W. H., To, K. H., Le, D., Bally, M. B., & Gorski, S. M. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9873-4 · Cited by 201
Brünner, N., Boysen, B., JIRUS, S., Skaar, T. C., Holst‐Hansen, C., Lippman, J., Frandsen, T. L., Spang‐Thomsen, M., Fuqua, S. A. W., & Clarke, R. C. (1997) · PubMed · Cited by 196
Measurement of steroid hormone receptors in breast cancer patients on tamoxifen
Encarnaci�n, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., & Osborne, C. K. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665801 · Cited by 194
Samaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M., Smith, M. J., Browning, D., Rawson, J., Smith, S. B., Barrett, J. T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0447 · Cited by 189
Arpino, G., Gutierrez, C., Weiss, H., Rimawi, M., Massarweh, S., Bharwani, L., De Placido, S., Osborne, C. K., & Schiff, R. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk151 · Cited by 188
Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer
Chang, X.-Z., Li, D.-Q., Hou, Y.-F., Wu, J., Lu, J.-S., Di, G.-H., Jin, W., Ou, Z.-L., Shen, Z.-Z., & Shao, Z.-M. (2007) · Breast Cancer Research · doi:10.1186/bcr1789 · Cited by 177
Autophagy, Mitochondrial Quality Control, and Oncogenesis
Jin, S. (2006) · Autophagy · doi:10.4161/auto.2.2.2460 · Cited by 174
Stoica, G. E., Franke, T. F., Moroni, M., Mueller, S., Morgan, E., Iann, M. C., Winder, A. D., Reiter, R., Wellstein, A., Martin, M. B., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206769 · Cited by 173
Gee, J. M. W., Harper, M. E., Hutcheson, I. R., Madden, T. A., Barrow, D., Knowlden, J. M., McClelland, R. A., Jordan, N., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2003-0705 · Cited by 170
Zhou, Q., Atadja, P., & Davidson, N. E. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.1.3549 · Cited by 160
Massarweh, S., & Schiff, R. (2006) · Endocrine-Related Cancer · doi:10.1677/erc.1.01273 · Cited by 159
Sharma, D., Blum, J., Yang, X., Beaulieu, N., MacLeod, A. R., & Davidson, N. E. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0011 · Cited by 158
In Vivo Evidence for the Role of CD44s in Promoting Breast Cancer Metastasis to the Liver
Ouhtit, A., Elmageed, Z. Y. A., Abdraboh, M. E., Lioe, T. F., & Raj, M. H. G. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070535 · Cited by 152
Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M. M., Tu, D., Shepherd, L. E., Pritchard, K. I., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4482 · Cited by 140
Creighton, C. J., Massarweh, S. A., Huang, S., Tsimelzon, A. I., Hilsenbeck, S. G., Osborne, C. K., Shou, J., Malorni, L., & Schiff, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1404 · Cited by 140
List, H.-J., Lauritsen, K. J., Reiter, R., Powers, C., Wellstein, A., & Riegel, A. T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102397200 · Cited by 134
Are peroxiredoxins tumor suppressors?
Neumann, C. A., & Fang, Q. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.04.007 · Cited by 133
Yuan, J. J., Murrell, G. A. C., Trickett, A. E., Landtmeters, M., Knoops, B., & Wang, M. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.04.006 · Cited by 125
Myers, E., Hill, A. D. K., Kelly, G., McDermott, E. W. M., O’Higgins, N. J., Buggy, Y., & Young, L. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1192 · Cited by 123
Estrogen and Progesterone in Normal Mammary Gland Development and in Cancer
Stingl, J. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0055-1 · Cited by 122
Katzenellenbogen, B. S., MILLER, M. A., Mullick, A., & Sheen, Y. Y. (1985) · Breast Cancer Research and Treatment · doi:10.1007/bf01806018 · Cited by 109
Oophorectomy for Breast Cancer: History Revisited
Love, R. R., & Philips, J. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.19.1433 · Cited by 107
Hormone Receptors and Breast Cancer
Habel, L. A., & Stanford, J. L. (1993) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036107 · Cited by 106
Russo, J., Reina, D., Frederick, J. J., & Russo, I. H. (1988) · PubMed · Cited by 93
Dowsett, M., & Haynes, B. P. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00365-0 · Cited by 88
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration
Johnston, S. R. D., Dowsett, M., Smith, I. E., Sacks, N., Haynes, B., Jarman, M., & Ebbs, S. R. (1993) · The Lancet · doi:10.1016/s0140-6736(05)80088-1 · Cited by 87
Caraci, F., Crupi, R., Drago, F., & Spina, E. (2011) · Current Drug Metabolism · doi:10.2174/138920011795713706 · Cited by 81
Regulation of Estrogenic Effects by Beclin 1 in Breast Cancer Cells
John, S., Nayvelt, I., Hsu, H., Yang, P., Liu, W., Das, G. M., Thomas, T., & Thomas, T. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5875 · Cited by 80
Crawford, A. C., Riggins, R. B., Shajahan‐Haq, A. N., Zwart, A. L., & Clarke, R. C. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008604 · Cited by 71
(2000) · doi:10.1002/1096-9896(2000)9999:9999 · Cited by 70
Tamoxifen versus Aromatase Inhibitors for Breast Cancer Prevention
Yue, W., Wang, J., Li, Y., Bocchinfuso, W. P., Korach, K. S., Devanesan, P. D., Rogan, E. G., Cavalieri, E. L., & Santen, R. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.925s.11.2 · Cited by 67
Johnston, S. R. D., Семиглазов, В. Ф., Manikhas, G. M., Spaëth, D., Romieu, G., Dodwell, D. J., Wardley, A. M., Neven, P., Bessems, A., Park, Y. C., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9726-1 · Cited by 66
Holloway, J. N., Murthy, S., & El‐Ashry, D. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0048 · Cited by 65
Denton, K. M., Shweta, A., & Anderson, W. P. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v13127 · Cited by 63
Tucker, A. N., Tkaczuk, K. A., Lewis, L. M., Tomic, D., Lim, C. K., & Flaws, J. A. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.08.027 · Cited by 62
Role of estrogen receptor α transcriptional coregulators in tamoxifen resistance in breast cancer
Girault, I., Bièche, I., & Lidereau, R. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.06.003 · Cited by 60
Kim, P. M., & Wells, P. G. (1996) · PubMed · Cited by 58
Ring, A. E., Šestak, I., Baum, M., Howell, A., Buzdar, A. U., Dowsett, M., Forbes, J., & Cuzick, J. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5545 · Cited by 58
Effect of P-glycoprotein Expression on Sensitivity to Hormones in MCF-7 Human Breast Cancer Cells
Clarke, R. C., Currier, S., Kaplan, O., Lovelace, E., Boulay, V., Gottesman, M. M., & Dickson, R. B. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1506 · Cited by 57
Pavlik, E. J., Nelson, K., Srinivasan, S. R., Powell, D. E., Kenady, D. E., DePriest, P. D., Gallion, H. H., & van Nagell, J. R. (1992) · PubMed · Cited by 55
(1992) · PubMed · Cited by 50
van den Berg, H., Lynch, M., Martin, J., Nelson, J., Dickson, G., & Crockard, A. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.107 · Cited by 44
Tan, T.-T., & White, E. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_5 · Cited by 43
Hurtubise, A., & Momparler, R. L. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0225-6 · Cited by 41
Ingle, J. N., Long, H. J., Loprinzi, C. L., Mailliard, J. A., Schaid, D. J., Krook, J. E., Dalton, R. J., Gesme, D. H., Windschitl, H. E., Pfeifle, D. M., et al. (1991) · Cancer · Cited by 37
Kurosumi, M. (2003) · Breast Cancer · doi:10.1007/bf02967633 · Cited by 24
Chang, M. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1236 · Cited by 24
Self-citationQuick, E. L., Parry, E. M., & Parry, J. M. (2007) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2007.10.021 · Cited by 19
Catecholestrogens in the Induction of Tumors in the Kidney of the Syrian Hamster
Liehr, J. G. (1997) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60873-x · Cited by 18
Cited by
Liquid biopsy in breast cancer: A comprehensive review
Alimirzaie, S., Bagherzadeh, M., & Akbari, M. R. (2019) · Clinical Genetics · doi:10.1111/cge.13514 · Cited by 332
The emerging role of zinc transporters in cellular homeostasis and cancer
Bafaro, E., Liu, Y., Xu, Y., & Dempski, R. E. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.29 · Cited by 307
Lu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119
Small nucleolar RNA and its potential role in breast cancer – A comprehensive review
Dsouza, V. L., Adiga, D., Sriharikrishnaa, S., Suresh, P. S., Chatterjee, A., & Kabekkodu, S. P. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188501 · Cited by 48
Deng, X., Xie, B., Li, Q., Xiao, Y., Hu, Z., Deng, X., Fang, P., Dong, C., Zhou, H.-B., & Huang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00525 · Cited by 43
Metadata
- Authors
- Chang, M.-S.
- Venue
- Biomolecules and Therapeutics
- Published
- 2012-05-31
- Volume
- 20
- Issue
- 3
- Pages
- 256-267
- ISSN
- 1976-9148 (ISSN-L)
- OpenAlex
- W2050831491
- Cited by
- 285
- References
- 116
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.